151751-Najiba-Chargi

370 CHAPTER 18 CORRELATION ANALYSIS Results from the correlation analyses are shown in Table 4. Significant low to moderately strong correlation coefficients is seen for SMI and BMI (r=0.49), SMI and age (r=-0.37), HGS and age (r=-0.46), gait speed and age (r=0.28) and for gait speed and HGS (r=-0.39). Table 4. Pearson correlation analysis for variables associated with sarcopenia. Measures SMI HGS Gait speed Age BMI SMI - 0.16 -0.15 -0.37** 0.49** HGS 0.16 - - 0.39** -0.46** -0.04 Gait speed -0.15 -0.39** - 0.28* 0.05 Age -0.37** -0.46** 0.28* - -0.02 BMI 0.49** -0.04 0.05 -0.02 - Legend: **. Correlation is significant at the 0.01 level (2-tailed) *. Correlation is significant at the 0.05 level (2-tailed) SURVIVAL ANALYSIS Results from the Kaplan Meier survival analysis are shown in Figures 1-4. As seen in Figures 1-3, the median overall survival appears to be shorter for patients treated with curative intent with high SMI compared with patients with low SMI (10.58 versus 13.34 months; log rank test p=0.29), but this difference was not statistically significant. The differences in OS between patients with low HGS compared with patients with high HGS (13.31 versus 13.17 months; log rank test p=0.25) and for patients with low gait speed compared with patients with high gait speed (11.94 versus 16.36 months; log rank test p=0.16) were not significant either. The median overall survival was significantly shorter for patients treated with curative intent with sarcopenia compared to patients without sarcopenia (12.07 versus 13.60months; log rank test p=0.02), as is illustrated in Figure 4. The overall 3-year survival rate was significantly shorter for patients treated with curative intent with sarcopenia compared to patients without sar- copenia (39% versus 75%; Wilcoxon Statistic 4.48, p=0.03) . Results from the univariate and multivariate cox regression analysis for overall survival are shown in Table 5. Sarcopenia (HR 2.80; 95% CI 1.14-6.88; p=0.03) and TNM-stage IV (HR 15.64; 95% CI 1.99-122.88; p=0.01) were significant prognostic factors for overall survival in univariate cox regression analysis. In mul - tivariate cox regression analysis, model 1 shows that sarcopenia (HR 2.66; 95% CI1.07-6.58; p=0.04) remained a significant prognostic factor for overall survival independent of age, Hb level, BMI, MUST-score and comorbidity. However, sarcopenia did not remain a significant prognostic factor when TNM-stage was included (model 2). TNM-stage IV was a significant prognostic factor for overall survival in multivariate cox regression analysis (HR 15.64; 95% CI 1.99-122.88; p=0.01). A subgroup analyses according to TNM-stage was performed, of which the results are shown in Table 6. Sarcopenia was a statistically significant prognostic factor for overall survival in patients with TNM-stage I-III (HR 9.19; 95% CI 1.07-78.74; p=0.04). However, sarcopenia was not a statistically significant prognostic factor for overall survival in patients with TNM-stage IV (HR 0.90; 95% 0.32-2.55; p=0.85).